Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | PALB2 K346Tfs*13 |
Therapy | Fluorouracil + Oxaliplatin + Veliparib |
Indication/Tumor Type | pancreatic ductal adenocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PALB2 K346Tfs*13 | pancreatic ductal adenocarcinoma | predicted - sensitive | Fluorouracil + Oxaliplatin + Veliparib | Case Reports/Case Series | Actionable | In a Phase I/II trial, Veliparib (ABT-888) in combination with Adrucil (fluorouracil) and Eloxatin (oxaliplatin) resulted in a partial response in a patient with metastatic pancreatic ductal adenocarcinoma harboring germline PALB2 K346Tfs*13 (reported as c.1037_1041delAAGAA) (PMID: 32669374; NCT01489865). | 32669374 |
PubMed Id | Reference Title | Details |
---|---|---|
(32669374) | A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. | Full reference... |